Successful cases of platinib (Pujihua) in the treatment of lung cancer with RET gene mutation

In recent years, with the rapid development of molecular targeted therapy, precise medication targeting RET gene mutations has become a new breakthrough in the treatment of non-small cell lung cancer (NSCLC). Platinib (Pralsetinib), as a highly selective RET kinase inhibitor, has been approved in many countries around the world for the treatment of RET fusion-positive advanced NSCLC patients. Its significant efficacy and controllable safety provide new hope for patients who lacked effective treatments in the past.

A 55 female patient was diagnosed with advanced lung adenocarcinoma, and genetic testing revealed the presence of a RET fusion mutation. The patient had previously received platinum-based chemotherapy, but the disease progressed rapidly. Then oral platinib treatment was started on the advice of the doctor. Just two months after treatment, imaging examinations showed that the primary lung lesions had shrunk significantly and the cervical lymph node metastasis had almost disappeared. The patient's symptoms such as cough and chest tightness were greatly relieved, and his physical score was significantly improved, reaching the standard of partial remission (PR). The treatment effect was maintained for more than 12 months.

Another62-year-old male patient had a complicated condition due to brain metastasis and bone metastasis, and his initial control with radiotherapy and chemotherapy was limited. After genetic testing confirmed that RET fusion was positive, platinib was used for treatment. A follow-up examination 3 months after treatment showed that the brain lesions had shrunk significantly, the bone metastases were stable, and the tumor marker levels had dropped. The patient's quality of life improves and he is able to resume daily activities. This case shows that platinib still has strong control power in patients with multiple metastases, especially showing good central nervous system activity in brain metastases.

These successful cases fully prove that platinib has the characteristics of rapid onset, high remission rate and long-lasting efficacy in the treatment of lung cancer with RET gene mutation. For patients who have failed chemotherapy or other treatments, platinib offers new possibilities for extending survival and improving quality of life. At the same time, this also emphasizes the importance of early genetic testing to ensure that patients can receive the most appropriate targeted treatment in a timely manner.

Reference link:https://www.drugs.com